Immutep (ASX: IMM) started a phase 3 clinical trial evaluating a potential combination therapy for first-line metastatic non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The Tacti-004 trial will assess the company's product candidate eftilagimod alfa in combination with US-based pharmaceutical company MSD's Keytruda therapy and chemotherapy, the filing said.
The trial will compare this regimen with placebo in about 750 patients globally, the filing added. Immutep expects to enroll the first patient into this study during the first quarter of fiscal 2025.
The trial will be conducted at over 150 clinical sites across more than 25 countries. Full approval to start the trial in the UK is expected soon, with additional approvals for multiple countries anticipated in the coming months.
Shares of the biotechnology company fell nearly 1% in recent Tuesday trade.
Price (AUD): $0.33, Change: $-0.003, Percent Change: -0.90%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。